Introduction {#s1}
============

Genome-wide association studies have been remarkably successful at identifying genetic variants associated with complex traits and diseases. To enable pharmacological and other interventions on these diseases, linking associated variants to causal intermediate phenotypes and processes is needed. A canonical example is the causal role of circulating LDL cholesterol in cardiovascular disease ([@bib21]). However, discovering clinically relevant intermediate phenotypes has so far remained challenging for most complex diseases. At the molecular level, *cis*-acting gene expression quantitative trait loci (*cis*-eQTLs) can be used to identify putative causal genes at disease-associated loci, but due to widespread co-expression between neighbouring genes ([@bib72]) and poor understanding of gene function, these approaches often identify multiple candidates whose functional relevance for the disease is unclear.

A promising approach to overcome the limitations of *cis*-eQTLs is *trans*-eQTL analysis linking disease-associated variants via signalling pathways and cellular processes (*trans*-acting factors) to multiple target genes. Although *trans*-eQTLs are widespread ([@bib71]), most transcriptomic studies in various cell types and tissues are still underpowered to detect them ([@bib1]). This is due to limited sample sizes of current eQTL studies, small effect sizes of *trans*-eQTLs, and the large number of tests performed (\>10^6^ independent variants with \>10^4^ genes). To reduce the number of tested phenotypes, co-expression analysis methods are sometimes used to aggregate individual genes to co-expressed modules capturing signalling pathways and cellular processes ([@bib66]). Such approaches have been successful in identifying *trans*-eQTLs in yeast ([@bib48]) as well as various human tissues ([@bib24]; [@bib40]; [@bib45]) and purified immune cells ([@bib54]; [@bib57]). An added benefit of co-expression modules is that they can often be directly interpreted as signatures of higher level cellular phenotypes, such as activation of specific signalling pathways or transcription factors ([@bib48]; [@bib74]).

Gene co-expression modules can be detected with various methods. Top-down matrix factorisation approaches such as independent component analysis (ICA) ([@bib25]), sparse decomposition of arrays (SDA) ([@bib24]) and probabilistic estimation of expression residuals (PEER) ([@bib65]) seek to identify latent factors that explain large proportion of variance in the dataset. In these models, a single gene can contribute to multiple latent factors with different weights. In contrast, bottom-up gene expression clustering methods such as weighted gene co-expression network analysis (WGCNA) ([@bib34]) seek to identify non-overlapping groups of genes with highly correlated expression values. Recently, both matrix factorisation and co-expression clustering methods have been further extended to incorporate prior information about biological pathways and gene sets, resulting in pathway-level information extractor (PLIER) ([@bib40]) and funcExplorer ([@bib31]), respectively. Out of these methods, ICA, WGCNA, SDA and PLIER have previously been used to find *trans*-eQTLs for modules of co-expressed genes ([@bib24]; [@bib40]; [@bib45]; [@bib54]; [@bib57]), but only a single method at a time. However, since different methods solve distinct optimisation problems, they can detect complementary sets of co-expression modules ([@bib66]), with recent benchmarks demonstrating that there is no single best co-expression analysis method ([@bib74]). Thus, applying multiple co-expression methods to the same dataset can aid *trans*-eQTL detection by identifying complementary sets of co-expression modules capturing a wider range of biological processes ([@bib74]).

Another aspect that can influence co-expression module detection is how the data is partitioned prior to analysis ([@bib66]). This is particularly relevant when data from multiple cell types or conditions is analysed together. When co-expression analysis is performed across multiple cell types or conditions, then the majority of detected gene co-expression modules are guided by differential expression between cell types ([@bib51]; [@bib69]). As a result, cell-type-specific co-expression modules can be missed due to weak correlation in other cell types ([@bib69]). One strategy to recover such modules is to perform co-expression analysis in each cell type separately ([@bib66]).

In this study, we performed comprehensive gene module *trans*-eQTL analysis across six major blood cell types and three stimulated conditions from five published datasets. To maximise gene module detection, we applied five distinct co-expression analysis methods (ICA, PEER, PLIER, WGCNA, funcExplorer) to the full dataset as well as individual cell types and conditions separately. Using a novel aggregation approach based on statistical fine mapping, we grouped individual *trans*-eQTLs to a set of non-overlapping loci. Extensive follow-up with gene set and transcription factor motif enrichment analyses allowed us to gain additional insight into the functional impact of *trans*-eQTLs and prioritise loci for further analyses. In addition to replicating two known monocyte-specific *trans*-eQTLs at the *IFNB1* ([@bib19]; [@bib51]; [@bib54]; [@bib58]) and *LYZ* loci ([@bib18]; [@bib53]; [@bib57]), we found that the *trans*-eQTL at the *ARHGEF3* locus detected in multiple whole blood datasets ([@bib40]; [@bib45]; [@bib57]; [@bib76]) was highly specific to platelets in our analysis. Finally, we also detected a novel association at the *SLC39A8* locus that controlled a group of genes encoding zinc-binding proteins in LPS-stimulated monocytes.

Results {#s2}
=======

Cell types, conditions and samples {#s2-1}
----------------------------------

We used gene expression and genotype data from five previously published studies from three independent cohorts ([@bib19]; [@bib18]; [@bib26]; [@bib42]; [@bib44]). The data consisted of CD4+ and CD8+ T cells ([@bib26]; [@bib42]), B cells ([@bib18]; [@bib42]), neutrophils ([@bib42]; [@bib44]), platelets ([@bib42]), naive monoctyes ([@bib19]; [@bib42]) and monocytes stimulated with lipopolysaccharide for 2 or 24 hr (LPS 2 hr, LPS 24 hr) and interferon-gamma for 24 hr (IFNγ 24 hr) ([@bib19]). The sample size varied from n = 226 in platelets to n = 710 in naive monocytes ([Figure 1A](#fig1){ref-type="fig"}). After quality control, normalisation and batch correction (see 'Materials and methods'), the final dataset consisted of 18,383 unique protein coding genes profiled in 3938 samples from 1037 unique genotyped individuals of European ancestries ([Figure 1B](#fig1){ref-type="fig"}). Even though the samples originated from five different studies, they clustered predominantly by cell type of origin ([Figure 1B](#fig1){ref-type="fig"}).

![Data, analysis workflow and results.\
(**A**) Sample sizes of cell types and conditions included in the analysis. LPS - lipopolysaccharide, IFNg - interferon-gamma. (**B**) Multidimensional scaling (MDS) analysis of the gene expression data and principal component analysis (PCA) of genotype data after quality control and normalisation. Cell types and conditions are colour-coded according to panel A. Genotyped samples from this study have been projected to the 1000 Genomes Project reference populations. (**C**) Following quality control, five co-expression methods were applied to two different data partitioning approaches: (1) gene expression profiles across all cell types and conditions were analysed together (integrated approach), (2) gene expression profiles from each cell type and condition were analysed separately (separate approach). (**D**) The number of gene modules detected from integrated and separate analyses. (**E**) For *trans*-eQTL analysis we used the estimated module activity profile ('eigengene') as our phenotype. To identify independent *trans*-eQTLs, we performed statistical fine mapping for all nominally significant (p-value\<5×10^−8^) associations and grouped together all associations with overlapping credible sets. (**F**) Manhattan plot of nominally significant (p-value\<5×10^−8^) *trans*-eQTLs. Each point corresponds to a gene module that was associated with the corresponding locus and is colour-coded by the cell type from panel A.](elife-58705-fig1){#fig1}

Detecting *trans*-eQTLs regulating modules of co-expressed genes {#s2-2}
----------------------------------------------------------------

We performed co-expression analyses with ICA, WGCNA, PLIER, PEER and funcExplorer on the full gene expression dataset (integrated approach) as well as on each cell type and condition separately (separate approach) ([Figure 1C](#fig1){ref-type="fig"}). In total, we obtained 482 gene modules from the integrated approach and 3509 from the separate clustering of different cell types ([Figure 1D](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). For every module, the methods inferred a single characteristic expression pattern ('eigengene') that represents the expression profiles of the module genes across the samples. Although implementation details varied between methods (see 'Materials and methods'), these eigengene profiles were essentially linear combinations of expression levels of genes belonging to the modules.

The number of detected modules and their sizes varied due to the properties and the default parameters of each method ([Figure 1D](#fig1){ref-type="fig"}). Although matrix factorisation approaches generally identified larger modules than clustering methods ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}), this is confounded by the fact that assigning genes to modules in matrix factorisation is fuzzy and requires the specification of arbitrary thresholds. Nevertheless, even though the number of modules for PEER and PLIER were initialised with identical values, PLIER consistently detected more modules with each module containing slightly fewer genes ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Similarly, funcExplorer detected more modules than WGCNA ([Figure 1D](#fig1){ref-type="fig"}) probably because funcExplorer was able to detect modules containing fewer genes (minimum of 5 *versus* 20 genes) if these were supported by functional enrichment ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

For *trans*-eQTL analysis, we included 6,861,056 common (minor allele frequency \>5%) genetic variants passing strict quality control criteria. First, we used linear regression implemented in MatrixEQTL ([@bib62]) package to identify all genetic variants nominally associated (p-value\<5×10^−8^) with the eigengenes of each of the 3991 co-expression modules detected across nine cell types and conditions. We performed *trans*-eQTL analysis in each cell type and condition separately. Next, we used SuSiE ([@bib73]) to fine map all significant associations to 864 independent credible sets of candidate causal variants ([Figure 1E](#fig1){ref-type="fig"}). Since we applied five co-expression methods to both integrated and cell-type-specific (separated) datasets, we found a large number of overlapping genetic associations. We thus aggregated overlapping credible sets from 864 associations to 601 non-overlapping genomic loci ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}; see 'Materials and methods'). We observed that some, especially smaller, co-expression modules were driven by strong *cis*-eQTL effects that were controlling multiple neighbouring genes in the same module. To exclude such effects, we performed gene-level eQTL analysis for 18,383 protein-coding genes and the 601 lead variants identified above. We excluded co-expression modules where the module lead variant was not individually associated with any of the module genes in *trans* (\>5 Mb away) and the overlap between the module genes and individually mapping *trans* genes was not significant according to the one-sided Fisher's exact test (Bonferroni adjusted p-value\<0.05) (see 'Materials and methods'). This step reduced the number of nominally significant *trans*-eQTL loci to 247 ([Figure 1F](#fig1){ref-type="fig"}; [Supplementary files 1](#supp1){ref-type="supplementary-material"}--[2](#supp2){ref-type="supplementary-material"}). Finally, to account for the number of co-expression modules tested, we used both Benjamini-Yekutieli false discovery rate (BY FDR) and Bonferroni correction (see 'Materials and methods'). The BY FDR 10% threshold reduced the number of significant associations to 38 and Bonferroni threshold retained only three significant loci, including loci near *IFNB1* ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}) and *LYZ* ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}) genes that have been previously reported in several other studies ([@bib19]; [@bib18]; [@bib51]; [@bib53]; [@bib57]; [@bib58]; [Table 1](#table1){ref-type="table"}). While the strong *trans*-eQTL signals at the *IFNB1* and *LYZ* loci were detected by all co-expression methods in both integrated and separate analyses, most associations were detected by only a subset of the analytical approaches ([Supplementary file 1](#supp1){ref-type="supplementary-material"}).

###### Literature-based replication of *trans*-eQTL loci near *IFNB1*, *LYZ* and *ARHGEF3* genes.

Linkage disequilibrium (r^2^) was calculated using European samples from the 1000 Genomes Phase 3 reference panel. The last column indicates if any of the associated modules had a significant overlap with the genes reported by the independent study according to one-sided Fisher's exact test after Bonferroni correction. The overlaps with individual modules are shown in [Supplementary file 5](#supp5){ref-type="supplementary-material"}. GHS - Gutenberg Health Study, FHS - Framingham Heart Study, CTS - Cardiogenics Transcriptomic Study, \* - largest observed r^2^ in the credible set.

  --------------------------------------------------------------------------------------------------------------------------------------------------
  *trans*-eQTL   Replication                                                                                                                  
  -------------- -------------- --------------------- ------------ --------------- --------------------- ------------ --------------- ------- ------
   *IFNB1*       rs13296842     Monocytes LPS 24 hr   [@bib19]     Fairfax_2014    Monocytes LPS 24 hr   rs2275888    0.57 (0.86\*)   FALSE   \-

  [@bib51]       Quach_2016     Monocytes LPS 6 hr    rs12553564   0.57 (0.86\*)   FALSE                 TRUE                                 

  [@bib54]       Fairfax_2014   Monocytes LPS 24 hr   rs2275888    0.57 (0.86\*)   FALSE                 \-                                   

  [@bib58]       Fairfax_2014   Monocytes LPS 24 hr   rs3898946    0.88            TRUE                  \-                                   

   *LYZ*         rs10784774     Monocytes naive,\     [@bib57]     GHS             Monocytes             rs11177644   0.79            TRUE    TRUE
                                LPS 2 hr,\                                                                                                    
                                LPS 24 hr,\                                                                                                   
                                IFNγ 24 hr                                                                                                    

  [@bib18]       Fairfax_2012   Monocytes             rs10784774   1               TRUE                  \-                                   

  [@bib53]       CTS            Monocytes             rs6581889    0.79            TRUE                  TRUE                                 

  *ARHGEF3*      rs1354034      Platelets             [@bib71]     eQTLGen         Blood                 rs1354034    1               TRUE    TRUE

  [@bib40]       Battle_2014    Blood                 rs1354034    1               TRUE                  \-                                   

  [@bib57]       GHS            Monocytes             rs12485738   0.6             FALSE                 \-                                   

   rs1344142     0.6            TRUE                  \-                                                                                      

  [@bib76]       FHS            Blood                 \-           \-              \-                    \-                                   

  [@bib45]       DILGOM07       Blood                 rs1354034    1               TRUE                  TRUE                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------

To characterise the general interpretability of the associated modules, we performed functional enrichment analysis for all modules associated with the 247 nominally significant loci ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). We found that 97% of the associated modules were enriched with at least one biological function from Gene Ontology, Reactome or KEGG. In contrast, in the gene-level analysis, only 86% of the loci showed significant enrichment in at least one tested cell type. However, this discrepancy could be partly due to the fact that gene-level analysis results in fewer associated genes, thus reducing the power to detect significant enrichments. Moreover, funcExplorer and PLIER modules are based on known gene annotations and are therefore expected to have high levels of enrichment by definition. We will now dissect two loci with interesting functional enrichment patterns in more detail.

Platelet-specific *trans*-eQTL at the *ARHGEF3* locus is associated with multiple platelet traits {#s2-3}
-------------------------------------------------------------------------------------------------

We found that the rs1354034 (T/C) variant located within the *ARHGEF3* gene is associated with three co-expression modules in platelets: one ICA module detected in integrated analysis (IC68, 1074 genes) and two co-expression modules detected in a platelet-specific analysis by PLIER (X6.WIERENGA_STAT5A_TARGETS_DN, 918 genes) and funcExplorer (Cluster_12953, five genes) ([Figure 2B](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The T allele increases the expression of the *ARHGEF3* gene in *cis* and the two lead variants are the same ([Figure 2A](#fig2){ref-type="fig"}). Furthermore, both the *cis* and *trans*-eQTLs colocalise with a GWAS hit for mean platelet volume (*cis* PP4 = 0.99, *trans* PP4 \>0.99 for all modules), platelet count (*cis* PP4 = 0.99, *trans* PP4 \>0.99 for all modules) and plateletcrit (*trans* PP4 \>0.99 for all modules) ([Figure 2A](#fig2){ref-type="fig"}; [@bib2]). Interestingly, *ARHGEF3* itself is not in any of the three modules and the module eigengenes are not strongly co-expressed with *ARHGEF3* (Pearson's r ranging from 0.07 to 0.33 in platelets). While IC68 and X6.WIERENGA_STAT5A_TARGETS_DN share 74 overlapping genes (one-sided Fisher's exact test p-value=0.003), none of the genes in Cluster_12953 is in any of the other modules.

![Platelet-specific *trans*-eQTL at the *ARHGEF3 locus*.\
(**A**) Regional plots showing colocalisation between GWAS signal for mean platelet volume ([@bib2]), *cis*-eQTL for *ARHGEF3* in platelets and *trans*-eQTL for a platelet-specific co-expression module detected by PLIER. *Cis* and *trans* credible sets (cs) are marked on the plots. The *cis* credible set consists of only the lead variant (rs1354034), which occludes the orange highlight. (**B**) Line graph showing that the association between the modules and *ARHGEF3* locus is platelet specific. In cell-type-specific clustering, only a single p-value from the corresponding cell type is available. The integrated modules have p-values from each of the cell types and the values are connected by a line. (**C**) Association between the *trans*-eQTL lead variant (rs1354034) and eigengene of module X6.WIERENGA_STAT5A_TARGETS_DN in platelets. ([**D**]{.smallcaps}) Association between the *trans*-eQTL lead variant (rs1354034) and *ARHGEF3* expression in platelets. (**E**) Manhattan plot of gene-level eQTL analysis for the *trans*-eQTL lead variant. Dark blue points highlight the genes in module X6.WIERENGA_STAT5A_TARGETS_DN. Light blue points show significantly associated genes (variant-level Benjamini-Hochberg FDR 5%) not included in the module. (**F**) Functional enrichment analysis of modules associated with *ARHGEF3* locus (see full results at <https://biit.cs.ut.ee/gplink/l/CY6ZukXhSq>). Empty cell indicates that no gene in the module is annotated to the corresponding term, enrichment p-value=1 shows that at least some of the genes in the module are annotated to the term, but not enough to report over-representation. The last column combines the FDR 5% significant genes from the gene-level analysis. The table shows adjusted enrichment p-values. GO - Gene Ontology, KEGG - Kyoto Encyclopedia of Genes and Genomes Pathways, REAC - Reactome Pathways.](elife-58705-fig2){#fig2}

Although the *ARHGEF3 trans*-eQTL has been detected in multiple whole blood *trans*-eQTL studies ([@bib40]; [@bib45]; [@bib71]; [@bib76]; [Table 1](#table1){ref-type="table"}), our analysis demonstrates that this association is highly specific to platelets and not detected in other major blood cell types ([Figure 2B](#fig2){ref-type="fig"}). Furthermore, even though *ARHGEF3* is expressed in multiple cell types, the *cis*-eQTL effect is also only visible in platelets ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Reassuringly, the *trans*-eQTL effect sizes in our small platelet sample (n = 216) are correlated (Pearson's r = 0.68, p-value=5.1×10^−12^) with the effects from the largest whole blood *trans*-eQTL meta-analysis ([@bib71]) (n = 31,684) ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). The platelet specificity of the *ARHGEF3* association is further supported by functional enrichment analysis with g:Profiler ([@bib55]), which found that both the PLIER module X6.WIERENGA_STAT5A_TARGETS_DN and target genes from the gene-level analysis were strongly enriched for multiple terms related to platelet activation ([Figure 2E](#fig2){ref-type="fig"}; <https://biit.cs.ut.ee/gplink/l/CY6ZukXhSq>). Cluster_12953, however, was enriched for cellular response to iron ion, suggesting that *ARHGEF3* might be involved in multiple independent processes ([@bib40]; [@bib61]). Altogether, these results demonstrate how a *trans*-eQTL detected in whole blood can be driven by a strong signal present in only one cell type.

*SLC39A8* locus is associated with zinc ion homeostasis in LPS-stimulated monocytes {#s2-4}
-----------------------------------------------------------------------------------

One of the novel results in our analysis was a locus near the *SLC39A8* gene that was associated (p-value=1.2×10^−9^) with a single co-expression module detected by funcExplorer (Cluster_10413) in monocytes stimulated with LPS for 24 hr ([Figure 3A--C](#fig3){ref-type="fig"}). The module consisted of five metallothionein genes (*MT1A*, *MT1F*, *MT1G*, *MT1H*, *MT1M*) all located in the same locus on chromosome 16 ([Figure 3D](#fig3){ref-type="fig"}). Although the *trans*-eQTL lead variant (rs75562818) was significantly associated with the expression of the *SLC39A8* gene ([Figure 3A and D](#fig3){ref-type="fig"}), the two association signals did not colocalise and the credible sets did not overlap ([Figure 3A](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), indicating that the *cis*-eQTL detected in naive and stimulated monocytes in our dataset is not the main effect driving the *trans*-eQTL signal. Furthermore, the expression of *SLC39A8* was only moderately correlated with the eigengene value of Cluster_10413 (Pearson's r = 0.27). Since *SLC39A8* is strongly upregulated (log~2~fold-change = 3.53) in response to LPS already at 2 hr ([Figure 4A](#fig4){ref-type="fig"}), we speculated that there might be a transient eQTL earlier in the LPS response. To test this, we downloaded the *cis-*eQTL summary statistics from the [@bib30] study that had mapped eQTLs in monocytes stimulated with LPS for 90 min and 6 hr ([@bib30]). Indeed, we found that the *cis*-eQTL 90 min after LPS stimulation colocalised with our *trans*-eQTL ([Figure 3A](#fig3){ref-type="fig"}) and this signal disappeared by 6 hr after stimulation ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}).

![Transient *cis*-eQTLs for *SLC39A8* is associated with the expression of seven metallothionein genes in *trans* in monocytes stimulated with LPS for 24 hr.\
(**A**) Regional plots comparing association signals between naive (rs11097779) and transiently induced *cis*-eQTLs (rs75562818) for *SLC39A8* and *trans*-eQTL (rs75562818) for a module of five co-expressed metallothionein genes. LPS-induced *cis*-eQTL summary statistics 90 min post stimulation (n = 134) were obtained from [@bib30]. (**B**) Graph showing that the association between the module and *SLC39A8* locus is stimulation specific. As this module was detected by a cell-type-specific clustering, only a single value from the corresponding cell type is available. ([**C**]{.smallcaps}) Association between *trans*-eQTL (rs75562818) and eigengene of funcExplorer module Cluster_10413 in monocytes after 24 hr of LPS stimulation. (**D**) Manhattan plot of gene-level eQTL analysis for rs75562818. Dark blue points highlight the genes in module Cluster_10413. Light blue points show significantly associated genes (variant-level Benjamini-Hochberg FDR 5%) not included in the module. (**E**) Functional enrichment analysis of the *SLC39A8* associated module (see <https://biit.cs.ut.ee/gplink/l/aohV4uKeT1> for full results). The last column combines the FDR 5% significant genes from the gene-level analysis. The table shows adjusted enrichment p-values. MTF1 - metal transcription factor 1. GO - Gene Ontology, WP - WikiPathways, REAC - Reactome Pathways, TF - transcription factor binding sites from TRANSFAC.](elife-58705-fig3){#fig3}

![Molecular mechanisms underlying the *SLC39A8 trans*-eQTL locus.\
(**A**) *SLC39A8* gene expression values (log~2~ intensities) across naive and stimulated monocytes. (**B**) Overview of the known regulatory interactions underlying the *cis* and *trans* eQTL effects at the *SLC39A8* locus. Figure adapted from [@bib36]. (**C**) Pairwise LD (r^2^ within 1000 Genomes European populations) between the *SLC39A8* variants highlighting missense variant (rs13107325), *trans*-eQTL (rs75562818), red blood cell distribution width (RBCDW) associated SNP (rs7692921) in our credible set and the *cis* lead variant from naive monocytes (rs11097779). LD was calculated using the LDlinkR (v.1.0.2) R package ([@bib43]).](elife-58705-fig4){#fig4}

To understand the function of the *SLC39A8* locus, we turned to the target genes. Gene-level analysis identified two more metallothionein genes (*MT1E* and *MT1X*) from the same locus as likely target genes ([Figure 3D](#fig3){ref-type="fig"}). Enrichment analysis with g:Profiler revealed that these genes were enriched for multiple Gene Ontology terms and pathways related to zinc ion homeostasis ([Figure 3E](#fig3){ref-type="fig"}, full results at <https://biit.cs.ut.ee/gplink/l/aohV4uKeT1>). Furthermore, the promoter regions of the seven genes were also enriched for the binding motif of the metal transcription factor 1 (MTF1) transcription factor (p-value=2.1×10^−4^, [Figure 3E](#fig3){ref-type="fig"}). Taken together, these results suggest that a transient eQTL of the *SLC39A8* gene 90 min after stimulation regulates the expression of 7 zinc-binding proteins 24 hr later. Multiple lines of literature evidence support this model ([Figure 4B](#fig4){ref-type="fig"}). First, the ZIP8 protein coded by the *SLC39A8* gene is a manganese and zinc ion influx transporter ([@bib46]). Secondly, *SLC39A8* is upregulated by the NF-κB transcription factor in macrophages and monocytes in response to LPS and this upregulation leads to increased intracellular Zn^2+^ concentration ([@bib36]). Third, Zn^2+^ influx increases the transcriptional activity of the metal transcription factor 1 (MTF1) ([@bib29]) and metallothioneins, which act as Zn^2+^-storage proteins, are well known target genes of the MTF1 transcription factor ([@bib33]). Finally, *SLC39A8* knockdown in mice leads to decreased expression of the metallothionein 1 (*MT1*) gene ([@bib36]).

To see if the *SLC39A8 trans*-eQTL might be associated with any higher level phenotypes, we queried the GWAS Catalog database ([@bib6]) with the ten variants from the *trans*-eQTL 95% credible set. We found that a lead variant for red blood cell distribution width (rs7692921) was one of the variants in our credible set and in high LD (r^2^ = 0.991) with the *trans*-eQTL lead variant ([Figure 4C](#fig4){ref-type="fig"}; [@bib28]). However, neither of the eQTL variants was in LD with a known missense variant (rs13107325) in the *SLC39A8* gene that has been associated with schizophrenia, Parkinson's disease and other traits ([Figure 4C](#fig4){ref-type="fig"}; [@bib49]).

Mediation analysis {#s2-5}
------------------

For three of the four *trans*-eQTL loci discussed above (*LYZ*, *ARHGEF3* and *SLC39A8*), we also detected an overlapping *cis*-eQTL effect on one or more *cis* genes. To test if the *cis*-eQTL effect might mediate the observed *trans* effect on the co-expression modules, we used mediation analysis. In all three cases, we detected a statistically significant mediation effect between the *cis* and *trans* associations ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}, [Supplementary file 4](#supp4){ref-type="supplementary-material"}). However, in all cases, the mediation explained only a small fraction of the total genotype effect on the co-expression module. There could be multiple reasons for this. First, since co-expression module eigengene values go through multiple transformations, this might introduce additional noise and thus reduce observed mediation effect ([@bib50]). Second, if there is a temporal delay between the *cis* and *trans* effects (as observed for *SLC39A8*) then we would not necessarily expect to detect mediation at the same time point, even if the *cis* eQTL is causal for the *trans* eQTL effect. Finally, multiple independent causal variants in the region that are in LD with each other could bias the mediation estimates ([Figure 3A](#fig3){ref-type="fig"}).

Replication of associations in independent datasets {#s2-6}
---------------------------------------------------

We first performed a literature-based replication to measure the overlap between the modules that map to the loci near *IFNB1*, *LYZ* and *ARHGEF3* with the genes reported by previous studies ([Table 1](#table1){ref-type="table"}, [Supplementary file 5](#supp5){ref-type="supplementary-material"}). All the modules associated with the *IFNB1* locus in monocytes stimulated with LPS for 24 hr (12 in total) had a significant overlap (one-sided Fisher's exact test, Bonferroni adjusted p-value\<0.05) with the *trans* genes reported by [@bib51]. At the *LYZ* locus, we compared the 30 modules detected in unstimulated monocytes with the *trans* genes reported by [@bib57] and [@bib53]. In the case of Rotival et al., 23 out of the 30 modules from our study had significant overlap with the 33 *trans* genes reported by Rotival et al. In contrast, only two of our modules had a significant overlap with the genes reported by Rakitsch and Stegle. Interestingly, only one *trans* associated gene was shared between Rotival et al. and ([@bib53]). We also evaluated the overlap for the three modules associated with the *ARHGEF3* locus and the 840 genes reported in the eQTLGen study ([@bib71]). Only one module, IC68, did not have a significant overlap but this could be due to its large size and the fuzzy definition of the ICA module membership. For *ARHGEF3* we also compared the modules with the 163 *trans* genes reported by [@bib45] where only one module (X6.WIERENGA_STAT5A_TARGETS_DN) had a significant overlap.

To further assess the replication of identified *trans*-eQTLs (after filtering for Benjamini-Yekutieli FDR\<10%), we compared associated modules in unstimulated monocytes, neutrophils and T-cells to matched cell types from three independent studies for which we had access to individual-level data: BLUEPRINT ([@bib8]), ImmVar ([@bib52]) and [@bib51]. We analysed 9 of the 38 *trans*-eQTLs that were associated with 40 different modules. We compared the overlap of gene modules and corresponding significant gene-level results (variant-level FDR \<5%) from these three independent studies. Unfortunately, we were not able to replicate any additional associations. Interestingly, even though the *LYZ and YEATS4 cis*-eQTL effect was present in all three studies, the *trans*-eQTL did not replicate in any of them. Since this *trans*-eQTL was previously detected by Rotival et al, this suggests that in addition to small sample sizes of the replication studies, there might be biological differences in how the samples were collected.

Discussion {#s3}
==========

Given that *trans*-eQTLs have been more difficult to replicate between studies and false positive associations can easily occur due to technical issues ([@bib10]; [@bib59]), it is increasingly important to effectively summarise and prioritise associations for follow-up analyses and experiments. We found that aggregation of credible sets of eigengene profiles from multiple co-expression methods ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) successfully reduced the number of independent associations, but this still retained 243 loci that we needed to evaluate. To further prioritise associations, we used gene set and transcription factor motif enrichment analysis of the *trans*-eQTL target genes. Although motif analysis is often underpowered, it can provide directly testable hypotheses about the *trans*-eQTL mechanism such as the MTF1 transcription factor that we identified at the *SLC39A8* locus. Similar approaches have also been successfully used to characterise *trans*-eQTLs involving IRF1 and IRF2 transcription factors ([@bib5]; [@bib19]).

A major limitation of co-expression-based approach for *trans*-eQTL mapping is that many true co-expression modules can remain undetected by various co-expression analysis methods ([@bib74]). We sought to overcome this by aggregating results across five complementary co-expression methods. We found that while all methods were able to discover strong co-expression module *trans*-eQTLs such as those underlying the *IFNB1* ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}) and *LYZ* ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}) associations, most co-expression module *trans*-eQTLs were only detected by a subset of the analysis methods. For example, the *ARHGEF3* association was detected by three of the five methods ([Figure 2B](#fig2){ref-type="fig"}) and *SLC39A8* co-expression module was found only by funcExplorer and only when samples from LPS-stimulated monocytes were analysed separately ([Figure 3B](#fig3){ref-type="fig"}). Since this module consisted of only seven strongly co-expressed genes, other methods were probably not well tuned to find it. Moreover, if the *trans*-eQTL locus controls a single or a small number of genes then co-expression-based approaches are probably not well suited to detect such associations and gene-level analysis is still required.

To maximise module discovery, we aggregated results from five co-expression analysis methods and two partitions of the same underlying data (integrated *versus* separate). While this reduced the number of tests compared to a standard gene-level analysis, it introduced an additional layer of complexity, because the same gene expression values contributed to multiple different co-expression modules and analytical settings. As a result, it is unclear how well calibrated our false discovery rate estimates are. Thus, we decided to first use a relaxed nominal significance threshold of p-value\<5×10^−8^, assuming that most of those associations were likely to be false positives. In our subsequent follow-up analyses, we only focused on four loci that we could either replicate in independent datasets (*IFNB1*, *LYZ*, *ARHGEF3*) or find significant support from the literature (*SLC39A8*).

Since eQTL datasets from purified cell types are still relatively small and single-cell eQTL datasets are even smaller ([@bib70]), it is tempting to perform *trans*-eQTL analysis on whole tissue datasets such as the brain or whole blood ([@bib71]). However, it remains unclear what fraction of cell type and condition-specific *trans*-eQTLs can be detected in whole tissue datasets collected from healthy donors. Although we were able to replicate the *ARHGEF3* association in the eQTLGen whole blood meta-analysis, because our fine mapped lead variant happened to be one of the 10,317 variants tested in eQTLGen, systematic replication requires genome-wide summary statistics that are currently lacking for *trans*-eQTL analyses. Secondly, tissue datasets can be biased by cell type composition effects. These can lead to spurious *trans*-eQTL signals, because genetic variants associated with cell type composition changes would appear as *trans*-eQTLs for cell-type-specific genes ([@bib71]). Furthermore, multiple studies have demonstrated that the co-expression signals in tissues are also largely driven by cell type composition effects ([@bib20]; [@bib47]; [@bib60]). Thus, even though PLIER detected the *ARHGEF3 trans*-eQTL in whole blood, this could have been at least partially driven by the change in platelet proportion between individuals ([@bib40]). Our analysis in purified cell types enabled us to verify that this was a truly platelet-specific genetic association.

Although both in the case of *ARHGEF3* and *SLC39A8,* we detected significant mediation between the expression level of the *cis* gene and the observed *trans*-eQTL effect, it explained only a small proportion of the total *trans* effect. Furthermore, there was only a modest correlation (Pearson's r between 0.07 and 0.33) between the *cis* gene expression and the corresponding *trans* co-expression module expression. In case of *SLC39A8* there seemed to be a temporal delay with the *cis*-eQTL being active early in LPS response and *trans*-eQTL appearing much later after proposed accumulation of the ZIP8 protein and increase in intracellular zinc concentration. Temporal delay has similarly been reported for the *trans*-eQTLs at the *INFB1* ([@bib19]) and *IRF1* ([@bib5]) loci. This suggests that if *cis* and *trans* effects are separated from each other either in time (early *versus* late response) or space (different cell types that interact with each other), then this might limit the power of methods that rely on genetically predicted gene expression levels to identify regulatory interactions ([@bib37]; [@bib39]; [@bib76]) and infer causal models. This can also have a negative impact on mediation analysis ([@bib4]; [@bib9]; [@bib77]), which seeks to estimate the proportion of *trans*-eQTL variance explained by the expression level of the *cis* gene. Altogether, our results indicate that limiting *trans*-eQTL analysis to missense variants and to variants that have been detected as *cis*-eQTLs in the same cell type might miss some true associations, because the *cis* effect might be active in some other, yet unprofiled, context.

We have performed a large-scale *trans*-eQTL analysis in six blood cell types and three stimulated conditions. We demonstrate that co-expression module detection combined with gene set enrichment analysis can help to identify interpretable *trans*-eQTLs, but these results depend on which co-expression method is chosen for analysis and how the input data are partitioned beforehand. We perform in-depth characterisation of two cell type specific *trans*-eQTL loci: platelet-specific *trans*-eQTL near the *ARHGEF3* gene and monocyte-specific associations near the *SLC39A8* locus. In both cases, the co-expression modules were enriched for clearly interpretable Gene Ontology terms and pathways, which directly guided literature review and more detailed analyses. We believe that applying co-expression and gene set enrichment based approaches to larger eQTL datasets has the power to detect many more additional associations while simultaneously helping to prioritise *trans*-eQTLs for detailed experimental or computational characterisation. A particularly promising avenue would be treating co-expression modules as complex traits for which multiple independent genetic associations could be mapped. These associations could subsequently be used in Mendelian randomisation analyses to infer causal intermediate phenotype for complex diseases ([@bib17]).

Materials and methods {#s4}
=====================

Datasets used in the analysis {#s4-1}
-----------------------------

### CEDAR {#s4-1-1}

The CEDAR dataset ([@bib42]) contained gene expression and genotype data from CD4+ T-cells, CD8+ T-cells, CD19+ B-cells and CD14+ monocytes, CD15+ neutrophils and platelets from up to 323 individuals. The raw gene expression data generated with Illumina HumanHT-12 v4 arrays were downloaded from ArrayExpress ([@bib3]) (accession E-MTAB-6667). The raw IDAT files were imported into R using the readIdatFiles function from the beadarray v2.28 ([@bib16]) Bioconductor package.

The raw genotype data generated by Illumina HumanOmniExpress-12 v1_A genotyping arrays were also downloaded from ArrayExpress (accession E-MTAB-6666). Genotype calling was performed with Illumina GenomeStudio v2.0.4, after which the raw genotypes were exported in PLINK format.

### [@bib26] {#s4-1-2}

[@bib26] generated gene expression and genotype data from CD4+ and CD8+ T cells from 297 unique donors. The raw gene expression data generated with Illumina HumanHT-12 v4 arrays were downloaded from Gene Expression Omnibus (accession GSE78840). The genotype data generated by Illumina HumanOmniExpress-12 v1_A genotyping arrays were obtained from the Estonian Genome Center, University of Tartu (<https://genomics.ut.ee/en/access-biobank>). Ethical approval was obtained from the Research Ethics Committee of the University of Tartu (approval 287/T-14).

### [@bib18], [@bib19] and [@bib44] {#s4-1-3}

[@bib18] profiled gene expression in CD19+ B cells from 282 individuals (ArrayExpress accession E-MTAB-945). [@bib19] profiled gene expression in naive CD14+ monocytes as well as in cells stimulated with lipopolysaccharide (LPS) for 2 or 24 hr and interferon-gamma for 24 hr from up to 414 individuals (accession E-MTAB-2232). [@bib44] profiled gene expression in CD15+ neutrophils from 93 individuals (accession E-MTAB-3536). The genotype data for all three studies were generated by Illumina HumanOmniExpress-12 genotyping arrays and were downloaded from European Genome-phenome Archive (accessions EGAD00010000144 and EGAD00010000520).

Genotype data quality control and imputation {#s4-2}
--------------------------------------------

We started with raw genotype data from each study in PLINK format and GRCh37 coordinates. Before imputation, we performed quality control independently on each of the three datasets. Briefly, we used Genotype harmonizer ([@bib12]) v1.4.20 to align the alleles with the 1000 Genomes Phase 3 reference panel and excluded variants that could not be aligned. We used PLINK v1.9.0 to convert the genotypes to VCF format and used the fixref plugin of the bcftools v1.9 to correct any strand swaps. We used 'bcftools norm \--`check-ref` x' to remove any remaining variants where the reference allele did not match the GRCh37 reference genome. Finally, we excluded variants with Hardy-Weinberg equilibrium p-value\>10^−6^, missingness \>0.05 and MAF \<0.01. We also excluded samples with more than 95% of the variants missing. Finally, we merged genotype data from all three studies into a single VCF file.

After quality control, we included 580,802 autosomal genetic variants from 1041 individuals for imputation. We used a local installation of the Michigan Imputation Server v1.2.1 ([@bib11]) to perform phasing and imputation with EAGLE v2.4 ([@bib38]) and Minimac4 ([@bib11]). After imputation, we used CrossMap.py v2.8.0 ([@bib78]) to convert genotype coordinates to GRCh38 reference genome. We used bcftools v1.9.0 to exclude genetic variants with imputation quality score R^2^ \<0.4 and minor allele frequency (MAF) \<0.05. We used PLINK ([@bib7]) v1.9.0 to perform LD pruning of the genetic variants and LDAK ([@bib63]) to project new samples to the principal components of the 1000 Genomes Phase 3 reference panel ([@bib67]). The Nextflow pipelines for genotype processing and quality control are available from GitHub (<https://github.com/eQTL-Catalogue/genotype_qc>).

Detecting sample swaps between genotype and gene expression data {#s4-3}
----------------------------------------------------------------

We used Genotype harmonizer ([@bib12]) v1.4.20 to convert the imputed genotypes into TRITYPER format. We used MixupMapper ([@bib75]) v1.4.7 to detect sample swaps between gene expression and genotype data. We detected 155 sample swaps in the CEDAR dataset, most of which affected the neutrophil samples. We also detected one sample swap in the [@bib44] dataset.

Gene expression data quality control and normalisation {#s4-4}
------------------------------------------------------

As a first step, we performed multidimensional scaling (MDS) and principal component analysis (PCA) on each dataset separately to detect and exclude any outlier samples. This was done after excluding the replicate samples and the samples that did not pass the genotype data quality control. Additional outliers were detected after quantile normalisation and adjusting for batch effects. The normalisation was performed using the lumiN function from the lumi v.2.30.0 R package ([@bib15]). Batch effects, where applicable, were adjusted for with the removeBatchEffect function from the limma v.3.34.9 R package ([@bib56]). After quality control to exclude outlier samples, the quantile normalised log~2~ intensity values from all datasets were combined. This was followed by regressing out dataset specific batch effects. Only the intensities of 30,353 protein-coding probes were used. Finally, the probe sets were mapped to genes. For genes with more than one corresponding probe set, the probe with the highest average expression was used. 18,383 protein-coding genes with unique Ensembl identifiers remained for co-expression analysis. We did not regress out any principal components from the gene expression data, as this can introduce false positives in *trans*-eQTL analysis due to collider bias ([@bib10]). In total, 3938 samples remained after the quality control ([Table 2](#table2){ref-type="table"}).

###### Number of samples included in the analysis from each study and each cell type.

  Cell type             Fairfax_2012   Fairfax_2014   Naranbhai_2015   Kasela_2017   CEDAR
  --------------------- -------------- -------------- ---------------- ------------- -------
  B cell                281            \-             \-               \-            266
  T cell CD4+           \-             \-             \-               279           294
  T cell CD8+           \-             \-             \-               267           281
  Neutrophil            \-             \-             93               \-            291
  Platelet              \-             \-             \-               \-            226
  Monocyte naive        \-             420            \-               \-            290
  Monocyte LPS 2 hr     \-             255            \-               \-            \-
  Monocyte LPS 24 hr    \-             325            \-               \-            \-
  Monocyte IFNγ 24 hr   \-             370            \-               \-            \-

Co-expression analysis {#s4-5}
----------------------

We applied five different methods to identify modules of co-expressed genes from the gene expression data. We used an expression matrix where rows correspond to genes and columns to individuals/samples as input for the methods. The gene expression profiles were centred and standardised prior to analysis. All methods infer gene co-expression modules, each of which can be described by a single expression profile ('eigengene') that captures the collective behaviour of corresponding genes in the module. Although the eigengenes are defined differently for matrix factorisation and co-expression clustering methods, there is a straightforward connection between the two definitions (see below more details). These eigengenes are treated as quantitative traits in the *trans*-eQTL analysis. To detect potential cell type and condition-specific modules, we applied the same methods also to the expression matrices from each of the nine cell types and conditions separately. To reduce complexity, we relied on default parameters recommended by the authors of each co-expression analysis method. Exceptions to this are stated below. Summaries of the co-expression analysis results from both integrated and cell-type-specific expression data are shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.

Co-expression clustering methods {#s4-6}
--------------------------------

### Weighted gene co-expression network analysis (WGCNA) {#s4-6-1}

The WGCNA method ([@bib34]) identifies non-overlapping co-expressed gene modules. Each of the modules is represented by its first principal component of expression values of genes in the module termed as module eigengene. We used the function blockwiseModules for automatic block-wise network construction and module identification with default parameters from the dedicated R package WGCNA (v.1.66). The number of modules was detected automatically by the algorithm, but the number of genes in a module was limited between 20 and 5000 genes. 

### funcExplorer {#s4-6-2}

FuncExplorer ([@bib31]) is a web tool that performs hierarchical clustering on gene expression values which is followed by automated functional enrichment analysis to derive the most biologically meaningful gene modules from the dendrogram. The expression data were uploaded to funcExplorer and the modules were detected using the following parameters: best annotation strategy, p-value threshold 0.01 for enrichment of Gene Ontology, KEGG and Reactome annotations. All other parameters were left to default values. Every funcExplorer gene module is characterised by the eigengene profile which, like in WGCNA, is the first principal component of module expression values calculated in the same way as in WGCNA. The number of modules is detected automatically by funcExplorer and the different modules consist of non-overlapping sets of genes, the default parameters limited module sizes between 5 and 1000 genes. The co-expression analysis results are available for browsing from <https://biit.cs.ut.ee/funcexplorer/user/2a29dfa6de6b8b733f665352735adaf5> where the option 'Dataset' includes the full selection of expression data used in this analysis. Dataset 'Merged_ENSG_expression' incorporates integrated samples from all cell types and conditions, 'CL_0000233_naive' stands for platelets, 'CL_0000236_naive' for B cells, 'CL_0000624_naive' for CD4+ T cells, 'CL_0000625_naive' for CD8+ T cells, 'CL_0000775_naive' for neutrophils, 'CL_0002057_naive' for monocytes and 'CL_0002057_IFNg_24_hr', 'CL_0002057_LPS_24 hr', 'CL_0002057_LPS_2 hr' include gene expression matrices from corresponding stimulated monocyte samples.

Matrix factorisation methods {#s4-7}
----------------------------

Matrix factorisation methods, such as ICA, PLIER and PEER, deconvolve the input gene expression matrix into two related matrices ([@bib66]). One of the matrices is the matrix of factor loadings for each sample and the other describes the gene-level weights of the factors. In the case of ICA, PLIER and PEER, we used the factor loadings as module eigengene profiles. For g:Profiler enrichment analysis we used the gene-level weights to define the genes that characterise the modules by choosing the ones that are the most influenced, that is the genes at both extremes of gene weight values (two standard deviations from the mean weights in this module). Thus, different modules can include overlapping sets of genes.

### Independent component analysis (ICA) {#s4-7-1}

The ICA ([@bib25]) method attempts to decompose gene expression measurements into independent components (factors) which represent underlying biological processes. The fastICA ([@bib41]) algorithm in R was run using the runICA function from the wrapper package picaplot v.0.99.7 (<https://github.com/jinhyunju/picaplot>). The number of components to be estimated was automatically detected by the implementation using a 70% variance cut-off value and maximum of 10 iterations (set with parameters var_cutoff = 70 and max_iter = 10). The ICA algorithm was run 15 times (n_runs = 15) with five cores (n_cores = 5) and only the components that replicated in every run were returned by the function. All other parameters were left to the default values.

### Pathway-level information extractor (PLIER) {#s4-7-2}

PLIER ([@bib40]) is a matrix decomposition method that uses prior biological knowledge of pathways and gene sets to deconvolve gene expression profiles as a product of a small number of latent variables (factors) and their gene weights. We performed PLIER analysis using the dedicated R package (v.0.99.0; downloaded from <https://github.com/wgmao/PLIER>) with the collection of 5933 gene sets as a prior information matrix priorMat available in the package comprising canonical, immune and chemgen pathways from MSigDB ([@bib35]), and various cell-type markers from multiple sources. The prior information matrix used as an input for this analysis is available from the PLIER analysis folder in the GitHub <https://github.com/liiskolb/coexpression-transEQTL/tree/master/analysis/PLIER> ([@bib32]; copy archived at <https://github.com/elifesciences-publications/coexpression-transEQTL>). PLIER was run with 100 iterations (max.iter = 100). Only the 16,440 genes appearing in both gene expression data and the pathway annotation matrix were used as input. For every input gene expression matrix we analysed, the initial number of latent variables (parameter k) was set using the num.pc function provided by the PLIER package.

### Probabilistic estimation of expression residuals (PEER) {#s4-7-3}

PEER ([@bib65]; [@bib64]) is a factor analysis method that uses Bayesian approaches to infer hidden factors from gene expression data that explain a large proportion of expression variability. We applied PEER method for co-expression analysis using the peer R package (v.1.0; downloaded from <https://github.com/PMBio/peer>) with default parameters, accounting also for the mean expression using the function PEER_setAdd_mean. The initial number of factors set by the function PEER_setNk was determined using the num.pc function from the PLIER package on each of the gene expression matrices we analysed. Therefore, the initial number of factors was set to the same value in case of PLIER and PEER. Since the number of modules estimated by the num.pc function were always larger than the number of detected modules, then this parameter value should not have a large impact on the final set of modules.

Relationship between the eigengene profiles of co-expression clustering and matrix factorisation methods {#s4-8}
--------------------------------------------------------------------------------------------------------

All eigengene profiles, regardless of the co-expression analysis method used, are linear combinations of expression levels of genes belonging to the corresponding module. In case of matrix factorisation methods, each gene is assigned a weight of belonging to a module, but for a specific module a vast majority of the genes are assigned weights that are close to zero. Similarly, one could think as if the weights of genes not belonging to a specific module from co-expression clustering analysis are set to zero.

We simulated a small example to show that, in a very simplified setting, the eigengenes from matrix factorisation and co-expression clustering analysis are highly correlated. First, we generated a data matrix (300 rows and 30 columns) that includes three orthogonal vectors plus noise that represent three different gene modules of sizes 150, 100 and 50 genes. Then, we performed principal component analysis (PCA) using the R function prcomp on the standardised full matrix (each gene has unit variance) as well as on the three submatrices (mimicking three clusters detected by co-expression clustering). In the first case, we extracted the eigenvectors of the first three principal components and in the second case, we extracted only the eigenvectors of first principal components from each of the three submatrices ([Figure 1---figure supplement 6](#fig1s6){ref-type="fig"}). We found that these two approaches yielded almost identical eigenvectors (up to a scaling factor).

Functional enrichment analysis {#s4-9}
------------------------------

We used the g:GOSt tool from the g:Profiler toolset ([@bib55]) via dedicated R package gprofiler2 (v.0.1.8) for functional enrichment analysis of gene modules. The short links to the full enrichment results were automatically generated using the parameter as_short_link = T in the function gost. The results shown in this paper were obtained with data version e99_eg46_p14_55317af. In case of general characterisation of gene modules and *trans* genes, we limited the data sources to Gene Ontology, Reactome and KEGG.

*Cis*-eQTL analysis and fine mapping {#s4-10}
------------------------------------

We performed *cis*-eQTL analysis using the qtlmap (<https://github.com/eQTL-Catalogue/qtlmap>) Nextflow ([@bib14]) workflow developed for the eQTL Catalogue project ([@bib27]). Briefly, we performed *cis*-eQTL analysis in a +/- 1 Mb window centered around each gene. We used the first six principal components (PCs) of both the gene expression and genotype data as covariates in the analysis. The number of genotype PCs was chosen based on the GTEx V8 analysis, which used the first five PCs ([@bib1]). While the number of gene expression PCs to be included in the analysis is sometimes optimised on each dataset to maximise eQTL discovery, we have found that beyond including the first few principal components the results usually change only minimally. The eQTL analysis was performed using QTLtools ([@bib13]).

For *cis*-eQTL fine mapping, we used the Sum of Single Effects (SuSiE) model ([@bib73]) implemented in the susieR v0.9.0 R package. We performed fine mapping on a +/- 1 Mb *cis* window centered around the lead eQTL variant of each gene using individual-level genotype and gene expression data. Prior to fine mapping, we regressed out six principal components of the gene expression and genotype data from the gene expression data. To identify significant eQTLs for QTL mapping, we performed Bonferroni correction for each gene to account for the number of variants tested per gene and then used Benjamini-Hochberg FDR correction to identify genes with FDR \< 0.1. The fine mapping Nextflow workflow for *cis*-eQTLs is available from GitHub (<https://github.com/eQTL-Catalogue/susie-workflow>).

Gene module *trans*-eQTL analysis and fine mapping {#s4-11}
--------------------------------------------------

The MatrixEQTL ([@bib62]) R package (v2.2) was used for *trans*-eQTL analysis to fit a linear model adjusted for sex, batch (where available) and the first three principal components of the genotype data. Before the analysis, the module eigengene profiles were transformed using the inverse normal transformation to reduce the impact of outlier eigengene values produced by some clustering methods. A total of 6,861,056 autosomal genetic variants with minor allele frequency (MAF) \>0.05 were tested. Due to the partial sharing of individuals between cell types and conditions, the eQTL analysis was performed in each cell type and condition separately. To achieve this, the eigenvectors from the integrated approach were split into cell-type-specific sub-eigenvectors before the analysis. The results from every analytical setting (data partitioning approach (n = 2), co-expression method (n = 5), cell type (n = 9), 90 *trans*-eQTL analyses in total) were then individually filtered to keep nominally significant variant-module associations (p-value\<5×10^−8^).

Next, we applied SuSiE ([@bib73]) to fine map the nominally significant associations to independent credible sets of variants. For every gene module, we started fine mapping from the lead variant (variant with the smallest association p-value for this module) and used a +/- 500,000 bp window around the variant to detect the credible sets. We continued fine mapping iteratively with the next best nominally significant variant outside the previous window to account for LD and continued this process until no variants remained for the gene module. This procedure resulted in a total of 864 credible sets across all cell types, co-expression analysis methods and data partitioning approaches (integrated and separate).

To aggregate and summarise overlapping associations, we combined all credible sets into an undirected graph where every node represents a credible set of a module from a triplet (data partitioning approach, co-expression method, cell type) and we defined an edge between two nodes if the corresponding credible sets shared at least one overlapping variant ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). The graph was constructed using the igraph R package. After obtaining the graph, we searched for connected components, that is subgraphs where every credible set is connected by a path, to combine the vast number of results into a list of non-overlapping loci (n = 601), which can no longer be interpreted as credible sets. For every component, we defined the lead variant by choosing the intersecting variant with the largest average posterior inclusion probability (PIP) value across all the credible sets in the component.

Genes in physical proximity often have correlated expressions levels and could thus manifest as co-expression modules in our analysis. Consequently, if one or more genes in such modules have *cis*-eQTLs, then these *cis* variant-module associations would also be detected by our approach. To differentiate *cis*-acting co-expressions module eQTLs from true *trans* associations, we decided to add an additional filtering step based on gene-level analysis. We performed gene-level eQTL analysis for individual gene expression traits of the 18,383 protein-coding genes and the 601 lead variants. The gene-level eQTL analysis was performed using the MatrixEQTL R package with the same settings and data transformations as in the module-level analysis described above. From every credible set component, we excluded the variant-module pairs together with corresponding credible sets where no *trans* associations (variant-level Benjamini-Hochberg FDR 5%) were included in the module. As *trans*-eQTLs we consider variants that act on distant genes (\>5 Mb away from the lead variant) and genes residing on different chromosomes. Furthermore, we performed one-sided Fisher's exact tests to assess the significance of overlap between the modules and gene-level *trans* analysis associations and excluded the variant-module pairs that did not have significant overlap with individual *trans* genes (Bonferroni-adjusted p-value\<0.05) ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). After this filtering step we repeated the process of aggregating credible sets, retaining 247 non-overlapping loci ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}).

To further account for the number of co-expression modules tested, we applied both Benjamini-Yekutieli false discovery rate (BY FDR) and Bonferroni correction at the level of each analytical setting ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). We applied the BY FDR 10% threshold to every module - lead variant pair from each of the 90 analytical settings (data partitioning approach, co-expression analysis method, cell type) and if a pair did not pass the threshold we excluded it together with the corresponding credible set(s) from the results. Bonferroni correction was applied in a similar manner with a threshold P-value \< $\frac{5 \times 10^{- 8}}{n_{i}}$, where $n_{i},i = 1,...,90,$ stands for the number of modules from the corresponding co-expression method and data partitioning approach. We repeated the graph-based aggregation process on the remaining credible sets individually from both correction methods and as a result the BY FDR 10% threshold reduced the number of significant associations to 38 and Bonferroni threshold to only 3 significant *trans*-eQTLs.

Colocalisation {#s4-12}
--------------

We downloaded GWAS summary statistics for 36 blood cell traits ([@bib2]) from the NHGRI-EBI GWAS Catalog ([@bib6]). We downloaded coloc ([@bib22]) R package v3.1 from bioconda ([@bib23]). The *cis*-eQTL colocalisation Nextflow workflow is available from GitHub (<https://github.com/kauralasoo/colocWrapper>). The same workflow was adjusted for *trans*-eQTL colocalisation.

*cis*-eQTL summary statistics for *SLC39A8* {#s4-13}
-------------------------------------------

([@bib30]) profiled gene expression in monocytes before and after stimulation with LPS, muramyl-dipeptide (MDP) and 5′-triphosphate RNA for 90 min and 6 hr. We downloaded the *cis*-eQTL summary statistics from ArrayExpress ([@bib3]) (accession E-MTAB-5631). Individual-level genotype data were not available for this study.

Mediation analysis {#s4-14}
------------------

We performed the mediation analysis using the R package mediation (v. 4.5.0) ([@bib68]). In case of *ARHGEF3*, *LYZ* and *SLC39A8,* we performed mediation tests for trios (*trans*-eQTL variant, *cis* gene, *trans* module) using a non-parametric bootstrap method (1000 simulations) for p-value and 95% confidence interval estimations of effects implemented in the package. We used the *cis*-gene expression as mediator, the *trans*-eQTL variant as the exposure variable and the module eigenvector as the outcome variable. We also included the same covariates as in the *trans*-eQTL mapping to the models. The analysis results include estimates for average causal mediation effects (ACME, also known as indirect effects), average direct effects (ADE) and for total effects (ACME + ADE). We considered that the *cis* gene partially mediates the gene module *trans* association if the estimates of indirect effects were statistically significant.

Replication of genetic associations {#s4-15}
-----------------------------------

For the identified *trans*-eQTLs (after filtering for BY FDR \<10%), we compared associated modules in unstimulated monocytes, neutrophils and T-cells to matched cell types from three independent studies: BLUEPRINT ([@bib8]), ImmVar ([@bib52]) and [@bib51]. The genotype and expression data from these studies were accessed and processed as described previously ([@bib27]).

We performed gene-level *trans*-eQTL analysis in these data for only the associations we detected in matching cell types after filtering for BY FDR \<10%, that is, 9 out of 38 lead variants. The analysis was performed using the MatrixEQTL R package with the same settings and data transformations as in the module-level analysis described above. For comparison with the modules, we used the list of significant genes (variant-level Benjamini-Hochberg FDR 5%) to perform one-sided Fisher's exact test to estimate the significance of the overlap.

For literature-based replication of *LYZ*, *IFNB1* and *ARHGEF3,* we extracted the corresponding *trans* genes from the independent studies where available (see [Table 1](#table1){ref-type="table"}). For each locus we evaluated the pairwise overlap between the associated modules and previously reported genes using one-sided Fisher's exact test. If not provided by the study, we used g:Convert tool from g:Profiler ([@bib55]) to map the *trans* genes to unique Ensembl IDs before the comparisons. For every locus we adjusted the p-values using Bonferroni correction across the modules.

We compared the modules associated with the *ARHGEF3* locus with the genes reported in eQTLGen database ([@bib71]) and by [@bib45]. The eQTLGen Consortium ([@bib71]) performed *trans*-eQTL analysis for 10,317 trait-associated genetic variants in 31,684 whole blood samples. For [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, we downloaded the summary statistics from <https://www.eqtlgen.org/trans-eqtls.html>. We extracted the results of [@bib45] from their supplementary material. Similarly, the results for comparing modules associate with *LYZ* and *IFNB1* loci from [@bib51], [@bib57] and [@bib53] were extracted from corresponding supplementary materials provided by the studies.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

In this manuscript, Kolberg et al. identified *trans*-eQTLs from isolated immune cell and blood gene expression data from thousands of samples isolated from individuals of European descent. After careful quality control, they used different approaches to identify co-expressed gene modules in these datasets, and used these modules for the eQTL scans. The careful analyses, including replication across different studies, indicates that the co-expression module-level approach is reliable for discovering *trans*-eQTLs with broad effects on gene expression.

**Decision letter after peer review:**

Thank you for submitting your article \"Co-expression analysis reveals interpretable gene modules controlled by *trans*-acting genetic variants\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Stephen CJ Parker as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Patricia Wittkopp as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Helene Ruffieux (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional analyses are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is \"in revision at *eLife*\". Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

Summary:

In this manuscript, Kolberg et al. identified *trans*-eQTLs from isolated immune cell and blood gene expression data from thousands of samples isolated from \~1000 individuals of European descent. They assessed the expression levels of \~18,000 genes. After careful quality control, they used five different approaches to identify co-expressed gene modules in these datasets. They identified nearly 4,000 co-expression modules. The sizes of these modules ranged from tens of genes to hundreds. They then summarized the expression of module genes by essentially calculating the first principle component of the module gene expression and labeled this summary statistic as the eigengene. They calculated the association of the eigengene with 6.8 million variants using linear regression and identified \~600 loci significant at the GWAS nominal threshold of 5e-8. They were able to determine that strong *cis* eQTLs were responsible for the associations of small modules. When they eliminated these *cis*-eQTL driven modules, they were left with \~300 associations. Correcting for multiple testing with an FDR procedure or Bonferroni approach reduced the number of significant associations to 140 and 4, respectively. They reassuringly identified two known *trans* eQTLs (*IFNB1* and *LYZ*). The authors then focus on the *ARHGEF3* locus, which was identified in a large blood eQTL meta-analysis, but here the authors show that the signal is platelet specific. This is an interesting approach to identify *trans* eQTL hotspots. All reviewers uniformly felt this work is of interest, but is in need of improvement in several areas. We list these below. If these areas can be satisfactorily addressed, the collection of candidate hits should constitute a valuable resource for generating hypotheses on eQTL regulation in specific cell types, to be explored in further research.

Essential revisions:

1\) For the *trans* eQTL loci identified with the co-expression approach, the authors need to map the expression of individual genes (which they do) and then assess the overlap between the genes in the modules and the genes that significantly map to the same loci individually. The significance of association for each of the genes would not necessarily be genome-wide significant (say 5-e8) but the authors can relax the significance criteria at various p-value thresholds and assess the overlap between the module genes and individually mapped genes. If there is a significant overlap, this further strengthens their argument that eigengene mapping is a useful approach to detect additional *trans* eQTLs that cannot be detected with individual gene mapping.

2\) The pros and cons of the different co-expression methods should be commented more extensively, in light of the data and question asked. The authors should discuss how the specificities of each method are reflected in the uncovered modules; the fact that conclusions are obtained from multiple methods does not justify eluding this discussion. For instance, Figure 1D seems to indicate that WGCNA tends to estimate fewer modules compared to funExplorer, any explanation why? Moreover, most of the co-expression methods involve a large number of tuning parameters. Although these parameters are provided in the Methods section, the strategy for choosing them is not described (data-driven? pilot analyses? are the default parameters always used, and if so, is it justified? etc) and the extent to which this may impact inference is not discussed. Finally, how do the different types of \"eigengenes\" produced by the co-expression methods (factor loadings, PCs, etc) affect eQTL mapping?

3\) The authors mention: \"In addition to replicating a number of established *trans*-eQTL loci\". This is vague, can replication rates be provided? Given that *trans* associations are particularly difficult to uncover, this information would be particularly useful to assess the potential of the approach. The current discussion focuses on dissecting the two loci *ARHGEF3* and *SLC39A8* and does not allow one to fully appreciate the overall effectiveness of the proposed module-based eQTL mapping. Replication rates for the uncovered hits may be easily obtained: e.g., using the independent study from Kim-Hellmuth et al. for monocytes (which the authors use to confirm signals for the *SLC39A8* locus) and, for the cell types with expression measured in two independent datasets (Table 1), one could \"discover\" the effects in the first dataset and \"validate\" them in the second dataset.

4\) The authors rightly point out that module-based eQTL mapping reduces multiple testing. However, given that a same gene can contribute to multiple modules and that several co-expression methods are used on the same data, another complex source of multiplicity is introduced which would also require proper adjustment. This has not been addressed nor acknowledged. At the very least, a caveat should be formulated.

5\) Another layer of complexity arises from the parallel analysis of datasets for each cell type and an \"integrated\" dataset combining all cell types. Hence, the same samples are analysed twice and the eQTL significance thresholds used in the paper again do not correct for this.

6\) What is the overlap between the genes that map to the *IFNB1* and *LYZ* loci in previous *trans* eQTL studies and the genes in the co-expression modules whose eigengenes mapped to these loci in this study? Is there a significant overlap? This should be reported. If there is no significant overlap, the potential reasons for this should be discussed.

7\) What is the overlap among the gene membership of the three modules whose eigengene mapped to the *ARHGEF3* locus? This is mentioned in the text but it is not clear how many genes are in each of the three modules. This locus was previously identified in a blood eQTL analysis. What is the overlap with the genes identified in the blood study and this study? If there is no significant overlap, the potential reasons for this should be discussed.

8\) The authors should perform a conditional analysis, such as causal inference modeling, network edge orienting, mendelian randomization, etc to identify if the *cis*-associated gene really regulates the *trans*-associated gene expression.
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Author response

> Essential revisions:
>
> 1\) For the trans eQTL loci identified with the co-expression approach, the authors need to map the expression of individual genes (which they do) and then assess the overlap between the genes in the modules and the genes that significantly map to the same loci individually. The significance of association for each of the genes would not necessarily be genome-wide significant (say 5-e8) but the authors can relax the significance criteria at various p-value thresholds and assess the overlap between the module genes and individually mapped genes. If there is a significant overlap, this further strengthens their argument that eigengene mapping is a useful approach to detect additional trans eQTLs that cannot be detected with individual gene mapping.

This is an excellent suggestion. Indeed, our original criteria of requiring only one gene to overlap between the co-expression module and gene-level analysis did not properly account for the fact that some modules are quite large and therefore a very small overlap might be purely due to chance. We now assessed the significance of overlap between the gene-level *trans* genes (BH FDR 5%) and every module associated with the corresponding locus (303 loci in total) using a one-sided Fisher's exact test.

Applying a more stringent threshold for each locus by requiring the associated modules to significantly overlap (Bonferroni adjusted Fisher's exact p-value \< 0.05) with the gene-level *trans* analysis results reduces the number of independent loci from 303 to 247. We replaced the previous filter (at least one *trans* gene in a module) with this more stringent threshold also in the manuscript. We included a Supplementary file 2 that for every locus-module pair includes the statistics of overlap sizes with the gene-level analysis.

> 2\) The pros and cons of the different co-expression methods should be commented more extensively, in light of the data and question asked. The authors should discuss how the specificities of each method are reflected in the uncovered modules; the fact that conclusions are obtained from multiple methods does not justify eluding this discussion. For instance, Figure 1D seems to indicate that WGCNA tends to estimate fewer modules compared to funExplorer, any explanation why?

Based on this comment we included a section to the Results comparing the modules detected by different methods in more detail:

"The number of detected modules and their sizes varied due to the properties and the default parameters of each method (Figure 1D). \[...\] Similarly, funcExplorer detected more modules than WGCNA (Figure 1D) probably because funcExplorer was able to detect modules containing fewer genes (minimum of 5 versus 20 genes) if these were supported by functional enrichment (Figure 1------figure supplement 1)."

> Moreover, most of the co-expression methods involve a large number of tuning parameters. Although these parameters are provided in the Materials and methods section, the strategy for choosing them is not described (data-driven? pilot analyses? are the default parameters always used, and if so, is it justified? etc) and the extent to which this may impact inference is not discussed.

We have now modified the subsection 'Co-expression analysis' in the Materials and methods in multiple places to clarify which parameters were used and what was the strategy for choosing the parameters. Specifically, we now also state that:

"To reduce complexity, we relied on default parameters recommended by the authors of each co-expression analysis method. Exceptions to this are stated below."

Initially, we decided to avoid extensive parameter searches as we felt that the "goodness" of identified modules could only be evaluated after completing the full *trans*-eQTL analysis and this would have been infeasible. However, after our manuscript was submitted, Way et al. \[1\] published a very through benchmarking multiple gene co-expression analysis methods, demonstrating that there is no single best method or set of parameters for co-expression analysis with different methods and parameter settings discovering biological features at different levels of granularity. In light of this, we have now added two references to Way et al. to the Introduction:

"\[...\] with recent benchmarks demonstrating that there is no single best co-expression analysis method [(Way et al., 2020)](https://paperpile.com/c/O7lWWo/6xhc). Thus, applying multiple co-expression methods to the same dataset can aid *trans*-eQTL detection by identifying complementary sets of co-expression modules capturing a wider range of biological processes [(Way et al., 2020)](https://paperpile.com/c/O7lWWo/6xhc)."

Finally, we agree with the reviewers that it would be interesting to try the five co-expression analysis methods that we have used here with a wide range of parameter settings to see how this affects *trans*-eQTL discovery, but we feel it would be out of the scope of the current manuscript. Moreover, if different parameter settings identify different co-expression modules and thus different *trans*-eQTLs, it would still remain unclear how to properly integrate those results and account for multiple testing (as the reviewers correctly highlight in point 4 below).

> Finally, how do the different types of \"eigengenes\" produced by the co-expression methods (factor loadings, PCs, etc) affect eQTL mapping?

One of the challenges of working with multiple co-expression analysis methods is that they often use very different terms to describe similar concepts, which makes it harder to realise how the methods are related to each other. This useful comment from the reviewers helped us realise that there is actually a straightforward connection between the factor loadings used by matrix factorisation methods (PLIER, ICA and PEER) and the first principal component (eigenvector) of the co-expression module used by the co-expression clustering methods (WGCNA and funcExplorer).

Let us consider a standardised gene expression matrix where each gene has zero mean and unit variance. For simplicity, let us assume that this matrix contains three orthogonal gene modules each containing a different number of genes. Now, if we perform a principal component analysis (simplest matrix factorisation approach) of this matrix, then the loadings of the first principal component (PC) will correspond to the eigengene of the largest co-expression module, the loadings of the second PC will correspond to the eigengene of the second-largest co-expression module and the loadings of the third PC will correspond to the eigengene of the third and final co-expression module. Similarly, if we cluster this gene expression matrix into three clusters corresponding to the three co-expression modules, then now the first PC of each cluster (and co-expression module) will correspond to its eigengene. To illustrate this behaviour, we now describe a small simulation experiment in Materials and methods (subsection "Relationship between the eigengene profiles of co-expression clustering and matrix factorisation methods").

Thus, even though matrix factorisation and co-expression clustering seem to be using different eigengene definitions, they are actually calculating a very similar property.

> 3\) The authors mention: \"In addition to replicating a number of established trans-eQTL loci\". This is vague, can replication rates be provided? Given that trans associations are particularly difficult to uncover, this information would be particularly useful to assess the potential of the approach. The current discussion focuses on dissecting the two loci ARHGEF3 and SLC39A8 and does not allow one to fully appreciate the overall effectiveness of the proposed module-based eQTL mapping. Replication rates for the uncovered hits may be easily obtained: e.g., using the independent study from Kim-Hellmuth et al. for monocytes (which the authors use to confirm signals for the SLC39A8 locus) and, for the cell types with expression measured in two independent datasets (Table 1), one could \"discover\" the effects in the first dataset and \"validate\" them in the second dataset.

We have now clarified the in the Abstract that we replicate three established *trans*-eQTL loci (*LYZ*, *IFNB1* and *ARHGEF3*). To substantiate this claim, we have performed additional analysis and added the following new section to the Results:

"Replication of associations in independent datasets

We first performed a literature-based replication to measure the overlap between the modules that map to the loci near *IFNB1*, *LYZ* and *ARHGEF3* with the genes reported by previous studies (Table 1, Supplementary file 5). \[...\] Only one module, IC68, did not have a significant overlap but this could be due to its large size and the fuzzy definition of the ICA module membership. For *ARHGEF3* we also compared the modules with the 163 *trans* genes reported by (Nath et al., 2017) where only the module X6.WIERENGA_STAT5A_TARGETS_DN had a significant overlap."

Unfortunately, we were not able to use Kim-Hellmuth et al. to replicate our *trans* associations, because neither the *trans*-eQTL summary statistics nor individual-level genotype data were available from that study. However, we were able to perform additional replication analysis for nine loci detected in neutrophils, T-cells and naive monocytes using three independent datasets (ImmVar, BLUEPRINT and Quach et al) for which we had access to individual-level genotype data. This new analysis is now also described in the Results (see also response to point 3):

"To further assess the replication of identified *trans*-eQTLs (after filtering with BY FDR 10%), we compared associated modules in unstimulated monocytes, neutrophils and T-cells to matched cell types from three independent studies for which we had access to individual-level data: BLUEPRINT [(Chen et al., 2016)](https://paperpile.com/c/O7lWWo/ky2c), ImmVar [(Raj et al., 2014)](https://paperpile.com/c/O7lWWo/F4M3) and Quach et al. [(Quach et al., 2016)](https://paperpile.com/c/O7lWWo/b9GDR). \[...\] Since this *trans*-eQTL was previously detected by Rotival et al., this suggests that in addition to small sample sizes of the replication studies, there might be biological differences in how the samples were collected."

Finally, we decided not to split our dataset by study and perform replication in that way, because this would have allowed us to replicate only half of associations that were detected by separate approach as the co-expression analysis in the integrated approach crucially depended on jointly analysing the full gene expression matrix. Moreover, reducing our discovery sample size in half would have probably allowed us to only assess replication for the strongest associations at the *IFNB1* and *LYZ* loci that we already have evidence for from the literature.

> 4\) The authors rightly point out that module-based eQTL mapping reduces multiple testing. However, given that a same gene can contribute to multiple modules and that several co-expression methods are used on the same data, another complex source of multiplicity is introduced which would also require proper adjustment. This has not been addressed nor acknowledged. At the very least, a caveat should be formulated.

We agree with this comment and we have added the following caveat to the Discussion:

"To maximise module discovery, we aggregated results from five co-expression analysis methods and two partitions of the same underlying (integrated versus separate). \[...\] In our subsequent follow-up analyses, we only focused on four loci that we could either replicate in independent datasets (*IFNB1*, *LYZ*, *ARHGEF3*) or find significant support from the literature (*SLC39A8*)."

> 5\) Another layer of complexity arises from the parallel analysis of datasets for each cell type and an \"integrated\" dataset combining all cell types. Hence, the same samples are analysed twice and the eQTL significance thresholds used in the paper again do not correct for this.

See response to point 4.

> 6\) What is the overlap between the genes that map to the IFNB1 and LYZ loci in previous trans eQTL studies and the genes in the co-expression modules whose eigengenes mapped to these loci in this study? Is there a significant overlap? This should be reported. If there is no significant overlap, the potential reasons for this should be discussed.

We included a new section "Replication of associations in independent datasets" to the manuscript summarising the overlaps with previous *trans*-eQTL studies (where available) in case of *ARHGEF3*, *IFNB1* and *LYZ* loci. We measured the pairwise overlap between the corresponding associated modules and the *trans* genes detected by previous studies. We evaluated the significance of the overlaps using one-sided Fisher's exact test and applied threshold of Bonferroni adjusted P-value \< 0.05. If Ensembl IDs were not provided by the study, we used g:Convert tool to map the *trans* genes to unique Ensembl IDs before comparing with our gene modules. We added the following paragraph to the Results:

"We first performed a literature-based replication to measure the overlap between the modules that map to the loci near *IFNB1*, *LYZ* and *ARHGEF3* with the genes reported by previous studies (Table 1, Supplementary file 5). \[...\] For *ARHGEF3* we also compared the modules with the 163 *trans* genes reported by (Nath et al., 2017) where only the module X6.WIERENGA_STAT5A_TARGETS_DN had a significant overlap."

> 7\) What is the overlap among the gene membership of the three modules whose eigengene mapped to the ARHGEF3 locus? This is mentioned in the text but it is not clear how many genes are in each of the three modules. This locus was previously identified in a blood eQTL analysis. What is the overlap with the genes identified in the blood study and this study? If there is no significant overlap, the potential reasons for this should be discussed.

See response to point 6 for more details. The sizes of the three modules are described in the first paragraph of the Section "Platelet specific *trans*-eQTL at the *ARHGEF3* locus is associated with multiple platelet traits" and the sizes of the overlaps with previously published gene lists are shown in Supplementary file 5.

> 8\) The authors should perform a conditional analysis, such as causal inference modeling, network edge orienting, mendelian randomization, etc to identify if the cis-associated gene really regulates the trans-associated gene expression.

Our colocalisation analysis suggests that for loci near *ARHGEF3*, *LYZ* and *SLC39A8* the *cis* genes might play a role in the regulation of corresponding *trans* associated gene modules (see also Figure 2A, Figure 1---figure supplement 4A, Figure 3A). We performed mediation analysis using the R package mediation (v 4.5.0) to further assess this. That is, we performed mediation tests for trios (SNP, *cis* gene, *trans* module) using a non-parametric bootstrap method (1,000 simulations) implemented in the package for P-value and confidence interval estimation. We also included the same covariates we used in eQTL mapping.

We have added the following paragraph to the Results:

"For three of the four *trans*-eQTL loci discussed above (*LYZ*, *ARHGEF3* and *SLC39A8*), we also detected an overlapping *cis*-eQTL effect on one or more *cis* genes. \[...\] Finally, multiple independent causal variants in the region that are in LD with each other could bias the mediation estimates (Figure 3A)."

To evaluate the mediation of *LYZ*, we performed mediation analysis for gene modules associated with the lead variant rs10784774 (chr12_69344099_A\_G) in unstimulated monocytes and in monocytes after 24 h of stimulation with IFNγ. In total, we analysed 57 mediation trios with *LYZ* gene expression as mediator and found 8 modules that showed significant mediation effect (Bonferroni corrected P-value \< 0.05), 7 of which were detected in IFNγ stimulated monocytes (Supplementary file 4).

In case of *IFNB1* we did not observe significant colocalising *cis* association in our analysis and therefore the assumptions for mediation analysis do not hold.
